Frontiers in Oncology, 2021 While functional studies of long noncoding RNAs (lncRNAs) have mostly focused on how they influence disease diagnosis and prognosis, the pharmacogenomic relevance of lncRNAs remains largely unknown.
Yuting Shan +5 more
doaj +1 more source
Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy : results from the BIG 02-98 phase III trial [PDF]
, 2012 Introduction: Pre-clinical data suggest p53-dependent anthracycline-induced apoptosis and p53-independent taxane activity. However, dedicated clinical research has not defined a predictive role for TP53 gene mutations. The aim of the current study was to
Viale, Giuseppe +16 more
core +5 more sources
BMC Cancer, 2010 Background To compare the activity and toxicity of docetaxel/carboplatin (DC) doublet vs single agent docetaxel (D) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC).
Pavlakou Georgia +9 more
doaj +1 more source
, 2016 Cytotoxic effects of docetaxel (DTX), docetaxel + ESWs (DTX ESWs), docetaxel-NBs (DTX NB), and docetaxel-loaded NBs + ESWs (DTX NB ESWs), in PC3 (panel A) and DU145 (panel B) cells.
Paolo Gontero (3534284) +12 more
core +1 more source
Docetaxel facilitates lymphatic-tumor crosstalk to promote lymphangiogenesis and cancer progression
BMC Cancer, 2018 Background Infiltration into lymphatic vessels is a critical step in breast cancer metastasis. Lymphatics undergo changes that facilitate metastasis as a result of activation of the cells lining lymphatic vessels, lymphatic endothelial cells (LECs ...
Alexandra R. Harris +2 more
doaj +1 more source
Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC) [PDF]
, 2009 Background NSCLC exhibits considerable heterogeneity in its sensitivity to chemotherapy and similar heterogeneity is noted in vitro in a variety of model systems.
Gyi, Mya +60 more
core +2 more sources
Chinese Journal of Lung Cancer, 2019 Background and objective Docetaxel is a commonly used anti-tumor drug in clinic, especially as the first-line drug for advanced non-small cell lung cancer (NSCLC). However, the molecular mechanism of docetaxel against NSCLC is still unclear.
Haichao SUN +4 more
doaj +1 more source
Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. [PDF]
PLoS ONE, 2012 BackgroundHormone-refractory prostate cancer remains hindered by inevitable progression of resistance to first-line treatment with docetaxel. Recent studies suggest that phenotypic changes associated with cancer may be transferred from cell-to-cell via ...
Claire Corcoran +10 more
doaj +1 more source
Docetaxel Labeled with Iodine 131 Radionuclide – A Possible New Anticancer Drug? (The Pilot Study)
Acta Medica, 2006 The cytotoxic potentials of the lipiodol emulsion with dissolved 131I-docetaxel, the 131I-lipiodol emulsion and non-labeled docetaxel were tested on the HeLa Hep2 cell line during 24 hours.
Jiří Pastera +2 more
doaj +1 more source
Docetaxel Enhances the Expression of STING Protein in PC3 Cells, and cGAMP Attenuates this Effect
Novelty in Biomedicine, 2020 Background: The stimulator of interferon genes (STING) agonist (cGAMP) kills the cancer cells through the activation of the innate immune system. PC3 cells are high in BTK and low in STING.
Shaghayegh Salimi +5 more
doaj +1 more source